Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials.

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

RCR in the NASCAR Cup Series at Dover Motor Speedway… Richard Childress Racing has four NASCAR Cup Series victories at Dover Motor Speedway. Dale Earnhardt won three times, including a sweep of both ...

Given the company’s popularity among hedge funds and the bullish sentiment surrounding it, Tempus AI, Inc. (NASDAQ:TEM) makes ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

(Yicai) July 17 -- Sino Biopharmaceutical said the Chinese drugmaker plans to invest no more than USD951 million to fully ...

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid ...

The plan – backed with a £2 billion ($2.68 billion) funding pledge – revolves around three overarching objectives; namely, ...

New class of Eureka Fellows selected for their outstanding efforts to build a healthier, more equitable world and will receive support to amplify their sustainability impact in Canada and around ...

Kisqali was approved for the new indication on the back of the NATALEE trial, in which adding Kisqali to standard treatment ...

During a live event, Matthew Lunning, DO, and participants discussed how identifying primary refractory and early relapsed ...